Vincenzo Sforza

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1354679/publications.pdf

Version: 2024-02-01

22	1,311	623574 14	713332 21
papers	citations	h-index	g-index

22	22	22	2577
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	RET Inhibitors in Non-Small-Cell Lung Cancer. Cancers, 2021, 13, 4415.	1.7	34
2	The safety of atezolizumab plus chemotherapy for the treatment of metastatic lung cancer. Expert Opinion on Drug Safety, 2020, 19, 775-783.	1.0	2
3	Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer. , 2020, 1, 117-130.		1
4	Pembrolizumab in lung cancer: current evidenceÂand future perspectives. Future Oncology, 2019, 15, 3327-3336.	1.1	4
5	EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer. Molecular Cancer Therapeutics, 2019, 18, 845-855.	1.9	58
6	Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. ESMO Open, 2019, 4, e000519.	2.0	5
7	Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open, 2018, 3, e000299.	2.0	29
8	Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program. Oncologist, 2018, 23, 1178-1187.	1.9	46
9	Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. ESMO Open, 2017, 2, e000177.	2.0	27
10	Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. ESMO Open, 2017, 2, e000229.	2.0	14
11	Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. World Journal of Gastroenterology, 2017, 23, 4675.	1.4	91
12	Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation. Oncotarget, 2017, 8, 67592-67604.	0.8	15
13	Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer. Oncotarget, 2017, 8, 68305-68316.	0.8	27
14	Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World Journal of Gastroenterology, 2016, 22, 6345.	1.4	94
15	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. Journal of Clinical Oncology, 2015, 33, TPS3634-TPS3634.	0.8	2
16	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. Journal of Clinical Oncology, 2015, 33, TPS789-TPS789.	0.8	2
17	Treatment of gastric cancer. World Journal of Gastroenterology, 2014, 20, 1635.	1.4	508
18	Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. Clinical Cancer Research, 2014, 20, 3775-3786.	3.2	89

#	Article	IF	Citations
19	Clinical management of advanced gastric cancer: The role of new molecular drugs. World Journal of Gastroenterology, 2014, 20, 14537.	1.4	41
20	Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multiâ€targeted kinase inhibitors in pimasertibâ€resistant human lung and colorectal cancer cells. International Journal of Cancer, 2013, 133, 2089-2101.	2.3	81
21	Increased TGF-Î± as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFRâ€“MET Interaction and Activation of MET Signaling in Colon Cancer Cells. Clinical Cancer Research, 2013, 19, 6751-6765.	3.2	130
22	Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?. Therapeutic Advances in Medical Oncology, 2013, 5, 51-72.	1.4	11